# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Voltaire (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN002-SYN
- Date: 2026-04-06
- Fictional facility: St. Posthumous Health Center
- Fictional author: Honorine Delacroix-Mensah, MD
- Calendar frame: modern shifted

## What we are working on

- Blood in the urine and difficulty passing water for three weeks; afraid it is something serious **S**
- Wants to finish the play he is staging and to keep writing, and does not want long stays in hospital **S**
- Has always taken many remedies of his own choosing and asks for something strong to make him sleep **S**

## Your goals

- Find the cause of the bleeding within three weeks. Target: 2026-04-22. Recorded outcome: CT urography in two days, cystoscopy in one week, resection in nine days; pathology reviewed at sixteen days. **S**
- Relieve the retention and recover kidney function. Target: 2026-04-22. Recorded outcome: Creatinine 1.68 to 1.22 mg/dL; voiding after the trial without catheter with a residual of 140 mL. **S**
- Treatment that controls bleeding and local symptoms while keeping him at home and writing. Target: 2026-05-27. Recorded outcome: Weekly radiotherapy under way; no clots or retention since the resection; writing most days. **S**
- Pain at or below 3 of 10 without sedation, falls, or constipation. Target: 2026-05-27. Recorded outcome: Pain 2 of 10 on scheduled acetaminophen and about one half tablet of oxycodone a day; no sedation. **S**
- A written plan for future care, with a named health care agent. Target: 2026-04-28. Recorded outcome: Health care agent named and a portable medical order completed at the wellness visit. **S**

## What we agreed to do

- Hematuria evaluation: urinalysis with microscopy, urine culture, urine cytology, blood count, kidney function, multiphasic CT urography with CT of the chest, and cystoscopy. Guideline: Microhematuria: AUA/SUFU Guideline (2020; amended 2025) (2025); CMID: Clinical Monitoring Intelligence Database, urologic cancer and benign prostatic hyperplasia monographs (2026) **S**
- Urology consultation for gross hematuria with chronic retention: cystoscopy, resection if a tumor is found, the voiding trial, and the meaning of the PSA. Guideline: Microhematuria: AUA/SUFU Guideline (2020; amended 2025) (2025); Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023 (2023); CMID: Clinical Monitoring Intelligence Database, urologic cancer and benign prostatic hyperplasia monographs (2026) **S**
- Retention: indwelling catheter now, tamsulosin at bedtime, catheter care teaching, then a trial without catheter with a bladder scan; IPSS and post-void residual at each visit. Guideline: Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023 (2023); Diagnosis, Prevention, and Treatment of Catheter-Associated Urinary Tract Infection in Adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America (2009); CMID: Clinical Monitoring Intelligence Database, urologic cancer and benign prostatic hyperplasia monographs (2026) **S**
- Medication review: stop the diphenhydramine sleep aid and the over-the-counter sodium phosphate enemas; keep polyethylene glycol; cut coffee to two cups a day, none after noon; sleep advice without sedatives. Guideline: American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults (2023); Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology (2018) **S**
- Shared decision on PSA testing: drawn before the catheter to interpret an enlarged, firm prostate, with the understanding that a raised value at 83 would lead to biopsy only if it would change treatment. Guideline: Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023 (2023); Prostate Cancer: Screening (2018) **S**
- Transurethral resection of the bladder tumor with examination under anesthesia, for diagnosis and staging. Guideline: Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024) (2024); NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer, Version 3.2026 (including non-urothelial histologies) (2026); EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer (2026); CMID: Clinical Monitoring Intelligence Database, urologic cancer and benign prostatic hyperplasia monographs (2026) **S**
- Geriatric assessment (G8 screen, function, falls, cognition, mood, nutrition, social support, and medicines) before choosing cancer treatment. Guideline: NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer, Version 3.2026 (including non-urothelial histologies) (2026); American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults (2023); Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology (2018) **S**
- Shared decision on treatment of muscle-invasive squamous cell carcinoma: radical cystectomy, trimodality bladder preservation, palliative hypofractionated radiotherapy, or symptom care alone; he chose weekly radiotherapy, 36 Gy in six fractions, given by the radiation oncology team. Guideline: Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024) (2024); NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer, Version 3.2026 (including non-urothelial histologies) (2026); EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer (2026); Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical Treatment (Hafeez S, et al.) (2017); CMID: Clinical Monitoring Intelligence Database, urologic cancer and benign prostatic hyperplasia monographs (2026) **S**
- Pain plan: scheduled acetaminophen; oxycodone 2.5 mg only if needed, no more than three doses a day, 15 tablets at a time from one prescriber; naloxone nasal spray; senna; the state prescription monitoring program checked; no alcohol, sleep aids, or anyone else's opium-based remedies; doses kept in a locked box; review within two weeks. Guideline: CDC Clinical Practice Guideline for Prescribing Opioids for Pain, United States, 2022 (2022); American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults (2023) **S**
- Palliative care team joins his care alongside radiotherapy for symptom control, goals of care, and support at home. Guideline: NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer, Version 3.2026 (including non-urothelial histologies) (2026); Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology (2018) **S**
- Advance care planning: name a health care agent and complete a portable medical order reflecting his wishes. Guideline: Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026) **S**

## Follow-up

- 2026-04-06: Primary care visit for three weeks of visible blood in the urine and difficult urination at 83 **S**
- 2026-04-13: One-week review of CT urography and kidney function; urology consultation with office cystoscopy **S**
- 2026-04-22: Review of resection pathology, diagnosis, geriatric assessment, trial without catheter, and shared decision on treatment **S**
- 2026-04-28: Subsequent annual wellness visit at 83 **S**
- 2026-05-06: Two-week review during weekly radiotherapy: symptoms, kidney function, voiding, and opioid safety **S**

This teaching document does not replace care from a qualified clinician.
